Original Article

Association between Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Lung Cancer

Authors: Scott A. Helgeson, MD, Mark R. Waddle, MD, Rebecca C. Burnside, MD, Yalew T. Debella, MD, Augustine S. Lee, MD, Charles D. Burger, MD, Zhuo Li, MS, Patrick W. Johnson, , Neal M. Patel, MD

Abstract

Objectives: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are the most commonly prescribed antihypertensives, with prior studies identifying a possible association between long-term use and increased rates of lung cancer. This study evaluated this potential association in a large population using propensity matching.

Methods: This was a population-based cohort study in a large healthcare system in three regions of the United States. Pairwise propensity score matching was performed using demographics and comorbidities. All of the adult patients in the healthcare system from January 1, 2000 to April 30, 2018 with at least 1 year of follow-up were included.

Results: In total, 3,253,811 patients with a median age of 59 (range 18–103) years were included. The ACEI group had a higher freedom from lung cancer versus controls at 15 years (98.47%, 95% confidence interval [CI] 98.41–98.54) versus 98.26%, (95% CI 98.20–98.33), whereas ARBs had similar rates versus controls at all time points. For patients diagnosed as having lung cancer, median all-cause survival was significantly higher in the ACEI (34.7 months, 95% CI 32.8–36.6) and ARB (30.9 months, 95% CI 28.1–33.8) groups than the control group (20.6 months, 95% CI 20.1–21.1).

Conclusions: This study showed lower rates of lung cancer with ACEI use and no difference in risk with ARBs. In addition, use of these medications was found to be associated with increased survival in those diagnosed as having lung cancer. This study supports the continued use of these medications without concern for increasing the risk of lung cancer.
Posted in: Lung Cancer1

This content is limited to qualifying members.

Existing members, please login first.

If you have an existing account please login now to access this article or view your purchase options.

Purchase only this article ($15)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics: 2014 update. Circulation 2014;129:e28–e292
 
2. Zhou M, Daubresse M, Stafford RS, et al. National trends in the ambulatory treatment of hypertension in the United States, 1997–2012. PLoS One 2015;10:e0119292
 
3. Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in human pathology. Amino Acids 2014;46:1727–1750
 
4. Trifilieff A, Da Silva A, Gies J. Kinins and respiratory tract diseases. Eur Respir J 1993;6:576–587
 
5. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005;16:293–299
 
6. Elizabeth E, Tatiana Sofia R-R, Oscar A, et al. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004;2:385–399
 
7. Sethi T, Rozengurt E. Multiple neuropeptides stimulate clonal growth of small cell lung cancer: effects of bradykinin, vasopressin, cholecystokinin, galanin, and neurotensin. Cancer Res 1991;51:3621–3623
 
8. Walther T, Menrad A, Orzechowski H-D, et al. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003;17:2061–2067
 
9. National Cancer Institute. SEER cancer stat facts: lung and bronchus cancer. https://seer.cancer.gov/statfacts/html/lungb.html. Accessed July 5, 2021
 
10. World Health Organization. Cancer. 2018. Available at: https://www.who.int/ news-room/fact-sheets/detail/cancer. Accessed September 2, 2019
 
11. Azoulay L, Assimes TL, Yin H, et al. Long-term use of angiotensin receptor blockers and the risk of cancer. PloS One 2012;7:e50893
 
12. Bhaskaran K, Douglas I, Evans S, et al. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ 2012;344:e2697
 
13. Chang C-H, Lin J-W, Wu L-C, et al. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 2011;29:3001–3007
 
14. Friis S, Sørensen HT, Mellemkjær L, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer. Cancer 2001;92:2462–2470
 
15. Gokhale M, Girman C, Chen Y, et al. Comparison of diagnostic evaluations for cough among initiators of angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Saf 2016;25:512–520
 
16. Hallas J, Christensen R, Andersen M, et al. Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based casecontrol study. Br J Clin Pharmacol 2012;74:180–188.
 
17. Lever AF, Hole DJ, Gillis CR, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998;352:179–184
 
18. Lindholm LH, Anderson H, Ekbom T, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001;358:539–544
 
19. Pasternak B, Svanström H, Callréus T, et al. Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011;123:1729–1736
 
20. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. Lancet Oncol 2011;12:65–82
 
21. Coleman CI, Baker WL, Kluger J, et al. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials. J Hypertens 2008;26:622–629
 
22. ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138 769 individuals. J Hypertens 2011;29:623–635
 
23. Sipahi I, Debanne SM, Rowland DY, et al. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010;11:627–636
 
24. Hicks BM, Filion KB, Yin H, et al. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 2018;363:k4209
 
25. Agostino M, William FW, Chung HT, et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Design 2003;9:751–761
 
26. Attoub S, Gaben AM, Al-Salam S, et al. Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann NY Acad Sci 2008;1138:65–72
 
27. Lindberg H, Nielsen D, Jensen BV, et al. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004;43:142–152
 
28. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens 2009;23:623
 
29. US Cancer Statistics Working Group. US Cancer Statistics Data Visualizations Tool. https://www.cdc.gov/cancer/uscs/dataviz/index.htm. Published June 2019. Accessed July 5, 2021
   
31. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174:773–785
 
32. Savarese G, Costanzo P, Cleland JGF, et al. A meta-analysis reporting effects of angiotensin-converting enzyme inhibitors and sngiotensin teceptor blockers in patients without heart failure. J Am Coll Cardiol 2013;61:131–142
 
33. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – Overview and meta-analyses. J Hypertens 2015;33:195–211
 
34. Sun F, Sun H, Zheng X, et al. Angiotensin-converting enzyme inhibitors decrease the incidence of radiation-induced pneumonitis among lung cancer patients: a systematic review and meta-analysis. J Cancer 2018;9:2123–2131
 
35. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Br J Cancer 2005;93:825–833.